EZH2 and neoplasm: In diffuse large B-cell lymphoma and follicular lymphoma, recurrent point mutations in the catalytic SET domain (Y641) of EZH2 increase H3K27me3 activity, repressing the expression of tumor suppressor genes that mediate differentiation, cell-cycle inhibition, and apoptosis [15–17].